Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 3
Submit an article Journal homepage
193
Views
28
CrossRef citations to date
0
Altmetric
Reviews

Malignant pleural mesothelioma: current treatments and emerging drugs

Carmen Belli San Raffaele Scientific Institute, Oncology Department, 60 Olgettina Street, 20132 Milan, Italy +390226437620; +390226437605; [email protected]
, MD PhD,
Dean Fennell Queen's University Belfast, Centre for Cancer Research and Cell Biology, Cancer Research UK, Ireland
,
Monica Giovannini San Raffaele Scientific Institute, Oncology Department, 60 Olgettina Street, 20132 Milan, Italy +390226437620; +390226437605; [email protected]
,
Giovanni Gaudino University of Piemonte orientale “A.Avogadro”, DISCAFF & DFB Center, Novara, Italy
&
Luciano Mutti Laboratory of Clinical Oncology, Department of Medicine, Local Health Unit 11, Borgosesia Vercelli, Italy
Pages 423-437 | Published online: 24 Jun 2009

Bibliography

  • Ramos-Nino M, Timblin C, Mossman B. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002;62:6065-9
  • Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006;103:10397-402
  • Xu A, Zhou H, Yu DZ, et al. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ Health Perspect 2002;110:1003-8
  • Kroczynska B, Cutrone R, Boccetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelioma cells and causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103:14128-33
  • Barbanti-Brodano G, Sabbioni S, Martini F, et al. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 2004;318:1-9
  • Bocchetta M, Miele L, Pass HI, et al. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 2003;22:81-9
  • Bocchetta M, Eliasz S, De Marco MA, et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008;68:1022-9
  • Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72
  • Flores RM. The role of PET in the surgical management of malignant mesothelioma. Lung Cancer 2005;49(Suppl 1):S27-32
  • Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998;113(Suppl 1):61S-5S
  • Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 2004;14:567-73
  • Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A lung cancer study group trial. J Thorac Cardiovasc Surg 1991;102:1-9
  • Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-92; discussion 1692-3
  • Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-46
  • Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-95
  • Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 2007;68:1366-74
  • Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-5
  • Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995;108:754-8
  • O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84:18-22
  • Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004;91:9-10
  • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
  • van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III Study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9
  • Tomek S, Emri S, Krejcy K, et al. Chemotherapy for malignant pleural mesothelioma: past results and recent development. Br J Cancer 2003;88:167-74
  • Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-17
  • Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003;5:98-106
  • Yap BS, Benjamin RS, Byrne M, et al. The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer 1978;42:1692-6
  • Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;3:136-47
  • Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44-5
  • Castagneto B, Zai S, Degiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005;28:223-6
  • Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60:259-63
  • Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-6
  • van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-5
  • Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003;97:2791-7
  • Jänne PA, Simon GR, Langer CJ, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesotelioma. J Clin Oncol 2008;26:1465-71
  • Andreopoulou E, Ross PJ, O'Brien ME, et al. The palliative benefit of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004;15:1406-12
  • Scagliotti GV, Shin D-M, Kindler HL, et al. Phase II study of Pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61
  • Baas P, Ardizzoni A, Grossi F, et al. EORTC Lung Cancer Group: the activit of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003;39:353-7
  • Calvert AH, Hughes AN, Calvert PM, et al. ALIMTA in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer 2000;29(Suppl 2):73-4
  • Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349-54
  • Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24(9):1443-8
  • Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-3
  • Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008;99:51-6
  • Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-7
  • Giaccone G, O'Brien ME, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002;38(Suppl 8):S19-24
  • Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984;15:961-4
  • Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005;48:429-34
  • Sørensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985;69(12):1431-2
  • Sørensen JB, Sundstrom S, Perell K, et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2:147-52
  • Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007;109:93-9
  • Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-704
  • Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002;20:274-81
  • Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival [abstract 2274]. Proc Am Soc Clin Oncol 2000;19:577a
  • Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998;273:14484-94
  • Dazzi H, Hasleton PS, Tachter N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924-6
  • Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006;54:399-407
  • Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101) [abstract 2535]. Proc Am Soc Clin Oncol 2003;22:630
  • Butnor KJ, Burchette JL, Sporn TA, et al. The spectrum of kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004;128:538-43
  • Langerak AW, van der Linden-van Beurden CA, Vesnel MA. Regulation of differential expression of platelet-derived growth factor alpha and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996;1305:63-70
  • Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? Surg Oncol 1993;2:235-40
  • Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB act as a chemoattractant for human malignant mesothelioma cells via PDGF receptor β-integrin 3β1 interaction. Clin Exp Metastasis 1998;16:529-39
  • Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-62
  • Catalano A, Rodinolis S, Rippo AR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrugresistant malignant mesothelioma cells. J Biol Chem 2004;279:46706-14
  • Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:6080-9
  • Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34
  • Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84
  • Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87
  • Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999;189:72-8
  • Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75
  • Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-8
  • Branchaud RM, MacDonald JL, Kane AB. Induction of angiogenesis by intraperitoneal injection of asbestos fibers. FASEB J 1989;3:1747-52
  • Roff M, Thompson J, Rodriguez MS, et al. Role of IkappaB alpha ubiquitination in signal-induced activation of NF-kappaB in vivo. J Biol Chem 1996;271:7844-50
  • An B, Goldfarb RH, Simian R, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induces apoptosis in transformed, but not normal, human fibroblast. Cell Death Differ 1998;5:1062-75
  • Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74
  • Strahl BD, Allis CD. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;403:41-5
  • Rippo MR, Moretti S, Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2003;23:7753-60
  • Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42
  • Jane PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-7
  • Garland L, Rankin C, Scott K, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-13
  • Cortese JF, Gowda AL, Wali A, et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006;(118):521-2
  • Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma [abstract 912]. Proc Am Soc Clin Oncol 2003;22
  • Villano J, Husain AN, Stadler WM, et al. A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) [abstract 7200]. Proc Am Soc Clin Oncol 2004;663
  • Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6
  • Porta C, Mutti L, Tassi G. Negative results of an italian group for mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-50
  • Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62:690-5
  • Catalano A, Gianni W, Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenetic treatments. Crit Rev Oncol Hematol 2004;50:101-9
  • Kindler HL, Karrison T, Lu C, et al. A multicenter, double-bind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM) [abstract 7019]. Proc Am Soc Clin Oncol 2005;23
  • Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14
  • Kindler HL, Chien K, Stadler WM, et al. SU5416 in malignant mesothelioma: a Univeristy of Chicago phase II consortium study [abstract 1359]. Proc Am Soc Clin Oncol 2001;20
  • Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-67
  • Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) [abstract 8063]. J Clin Oncol 2008;26(Suppl):439s
  • Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol 2006;24(18S):7081
  • Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
  • Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005;48:291-6
  • Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies [abstract]. Lung Cancer 2003;41(Suppl 2):S11
  • Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor Bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008;61:549-58
  • Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47
  • Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31
  • Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9
  • Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701
  • Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995;36:488

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.